

## **IN THE CLAIMS**

1. (Withdrawn) A method of preparing cells as a cancer therapy for administration to a subject with cancer comprising culturing the cells in the presence of an MIF antagonist.
2. (Withdrawn) The method of Claim 1 in which the MIF antagonist is selected from the group consisting of anti-MIF antibodies, MIF antisense cDNA, and antagonists of MIF ligand:receptor binding.
3. (Withdrawn) A method of preparing cells as a cancer therapy for administration to a subject with cancer comprising culturing the cells in the presence of anti-MIF antibodies.
4. (Withdrawn) The method of Claim 3 in which the anti-MIF antibodies are monoclonal.
5. (Withdrawn) The method of Claim 4 in which the monoclonal anti-MIF antibodies are selected from the group consisting of human monoclonal antibodies, humanized monoclonal antibodies, chimeric monoclonal antibodies and single-chain monoclonal antibodies.
6. (Withdrawn) A method of preparing a cellular composition as a cancer therapy for administration to a subject with cancer comprising incubating cells of the composition in the presence of (a) at least one tumor antigen and (b) anti-MIF antibodies.
7. (Withdrawn) A method of preparing autologous cells for administration to a subject with cancer comprising the step of incubating the cells in the presence of an agent, said agent selected from the group consisting of anti-MIF antibodies, MIF-binding fragments thereof, or both.
8. (Withdrawn) A method of preparing autologous cells for administration to a subject with cancer comprising the step of incubating the cells in the presence of (a) at least one tumor antigen and (b) an agent, said agent selected from the group consisting of anti-MIF antibodies, MIF-binding fragments thereof, or both.

9. (Withdrawn) The method of Claim 7 in which the autologous cells comprise immune cells.

10. (Withdrawn) The method of Claim 7 in which the autologous cells comprise T cells.

11. (Withdrawn) The method of Claim 7 in which the autologous cells comprise CD8<sup>+</sup> cells.

12. (Currently Amended) A cellular composition for administration to a subject with cancer, comprising isolated lymphoid cells incubated with an anti-MIF antibody and a tumor antigen, wherein said lymphoid cells exhibit enhanced cytotoxic T-lymphocyte (CTL) activity toward said antigen.

13. (Canceled).

14. (Previously Presented) The cellular composition of Claim 12 in which the incubation with an anti-MIF antibody and a tumor antigen is *ex vivo*.

15. (Previously Presented) The cellular composition of Claim 12 that is isolated from unbound anti-MIF antibody.

16. (Currently Amended) The cellular composition of Claim [[13]] 12 that is isolated from unbound anti-MIF antibody and unbound tumor antigen.

17. (Canceled).

18. (Previously Presented) The cellular composition of Claim 12 in which the isolated cells comprise T cells.

19. (Previously Presented) The cellular composition of Claim 12 in which the isolated cells comprise CD8<sup>+</sup> cells.

20. (Withdrawn) A method for treating cancer, comprising administering to a subject in need thereof the composition of Claim 12.

21. (Currently Amended) A cellular composition for administration to a subject with

cancer, comprising:

autologous immune cells from said subject, wherein said autologous immune cells are incubated *in vitro* with an anti-MIF antibody and cancer cells, and wherein said immune cells exhibit enhanced targeting of said cancer cells.

22. (Previously Presented) The cellular composition of Claim 21, wherein the autologous immune cells comprise T cells.

23. (Previously Presented) The cellular composition of Claim 21, wherein the cancer cells are autologous cancer cells.